2023
Maintaining Engagement in Adults with Neurofibromatosis Type 1 to Use the iCanCope Mobile Application (iCanCope-NF)
Buono F, Larkin K, Pham Q, De Sousa D, Zempsky W, Lalloo C, Stinson J. Maintaining Engagement in Adults with Neurofibromatosis Type 1 to Use the iCanCope Mobile Application (iCanCope-NF). Cancers 2023, 15: 3213. PMID: 37370823, PMCID: PMC10296339, DOI: 10.3390/cancers15123213.Peer-Reviewed Original ResearchPsychosocial treatmentsContingency managementSemi-structured interviewsChronic painGoal settingEngagement dataParticipants' experiencesCurrent studyNeurofibromatosis type 1EngagementCustomized mobile applicationConsistent issueAdultsMixed methodologyPositive feedbackMixed methodsExperienceMoodPhysical activityMobile applicationsGoalPain treatmentSleepSubset of dataIndividuals
2021
Innovation in the treatment of persistent pain in adults with Neurofibromatosis Type 1 (NF1): Implementation of the iCanCope mobile application
Buono FD, Lalloo C, Larkin K, Zempsky WT, Ball S, Grau LE, Pham Q, Stinson J. Innovation in the treatment of persistent pain in adults with Neurofibromatosis Type 1 (NF1): Implementation of the iCanCope mobile application. Contemporary Clinical Trials Communications 2021, 25: 100883. PMID: 35036627, PMCID: PMC8743203, DOI: 10.1016/j.conctc.2021.100883.Peer-Reviewed Original ResearchNeurofibromatosis type 1Pain symptomsNF1 populationType 1Chronic pain symptomsSelf-management treatmentPersistent painTreatment satisfactionTreatment optionsControl studySix weeksPainPsychometric evaluationContingency managementInitial effectivenessGenetic disordersThird groupSymptomsAdultsTreatmentPopulationDifferent populationsGroupParticipants' experiencesGreater reach